AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17876014
Drug: Erlotinib (Erl)
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib (Erl) 150 mg daily combined with Bevacizumab (Bev) 10 mg/kg every 2 weeks
Trial: 17876014
Drug: Bevacizumab (Bev)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (Bev) 10 mg/kg every 2 weeks
Trial: 16420077
Drug: Tiagabine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (4 mg/day initiated, flexibly dosed to a maximum of 16 mg/day)
Trial: 29893592
Drug: D-aspartic acid
RxNorm normalized name: (3S)-3-methyl-D-aspartic acid
DrugBank: D-Aspartic Acid (DB02655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-aspartic acid (DAA) 3 g/day for 2 weeks
Trial: 29893592
Drug: Placebo 3
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 g/day for 2 weeks
Trial: 12860833
Drug: Aldosterone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone with L‐NMMA
Trial: 16520409
Drug: L‐NMMA alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA alone
Trial: 15531664
Drug: Diet containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet containing 3 g beta-glucan/d from barley
Trial: 15531664
Drug: Diet containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet containing 6 g beta-glucan/d from barley
Trial: 3107442
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 (0.1 mg X kg‐1)
Trial: 6742535
Drug: Midazolam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.15 mg X kg‐1)
Trial: 27451354
Drug: Mindfulness-Based Compassionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Compassionate Living (MBCL) in addition to treatment as usual (TAU)
Trial: 24350814
Drug: Fluoxetine (n=10)
RxNorm normalized name: fluoxetine 10 MG
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (n=10)
Trial: 11137414
Drug: IV diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV diclofenac (0.7 mg/kg bolus followed by 0.15 mg/kg/hr infusion)
Trial: 9171947
Drug: Fluoxetine (FX)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FX) 40 mg
Trial: 26718419
Drug: Intraduodenal capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraduodenal capsaicin infusion (1.5 mg pure capsaicin)
Trial: 20492507
Drug: Mitoquinone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoquinone (40 mg)
Trial: 20492507
Drug: Mitoquinone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoquinone (80 mg)
Trial: 18096840
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment with continuous intravenous insulin
Trial: 18096840
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with subcutaneous insulin QID as needed
Trial: 4549500
Drug: Conventional syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional syringe injection
Trial: 10599773
Drug: Metrifonate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (30 to 60 mg based on weight or a 50-mg fixed dose)
Trial: 1663965
Drug: Lisinopril (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (average dose 18.8 mg)
Trial: 1663965
Drug: Nifedipine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (average dose 37.4 mg)
Trial: 1663965
Drug: Nifedipine (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (highest dose level)
Trial: 6104172
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT), administered three times a week, with a minimum of eight treatments and a maximum of twelve.
Trial: 6104172
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no electricity used, no convulsion induced), administered the same treatment procedure as ECT.
Trial: 30711853
Drug: Trauma-Focused Cognitive-Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT)
Trial: 28401197
Drug: Traditional technique
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional technique with deeper insertion of smaller implants (control group)
Trial: 26010803
Drug: Modified preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified preparation (300 mg of aspirin and 75 mg of clopidogrel bisulfate; with 200 mg of cilostazol added for HTPR to clopidogrel)
Trial: 26010803
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation (100 mg of aspirin and 75 mg of clopidogrel)
Trial: 26010803
Drug: Modified preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified preparation
Trial: 24130381
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (PPI and amoxicillin for 5 days followed by PPI, clarithromycin and tinidazole for 5 days)
Trial: 24130381
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (PPI, clarithromycin and amoxicillin for 10 days)
Trial: 21823278
Drug: Suxiaojiuxin pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxiaojiuxin pill
Trial: 15595714
Drug: Frontal Assessment
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frontal Assessment Battery (FAB) administered to patients with mild Alzheimer's disease (AD)
Trial: 15595714
Drug: Frontal Assessment
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frontal Assessment Battery (FAB) administered to normal controls
Trial: 15595714
Drug: Frontal Assessment
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frontal Assessment Battery (FAB) administered to patients with frontotemporal dementia (FTD)
Trial: 11488449
Drug: Boswellia serrata
RxNorm normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boswellia serrata gum resin (900 mg daily divided in three doses for 6 weeks)
Trial: 11488449
Drug: Sulfasalazine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (3 gm daily divided in three doses for 6 weeks)
Trial: 8097788
Drug: Aerosolized pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized pentamidine (AP), 60 mg biweekly via System 22 nebulizer
Trial: 3307496
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment specific for substance abuse
Trial: 21920208
Drug: 1.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg/kg propofol
Trial: 19001327
Drug: Concurrent biochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b
Trial: 8674322
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Escherichia coli endotoxin
Trial: 8674322
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of saline placebo
Trial: 8674322
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (with endotoxin)
Trial: 1863928
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy with the aid of a personal computer
Trial: 6347108
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV methylprednisolone 125 mg every six hours for three days
Trial: 6347108
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV methylprednisolone 40 mg every six hours for three days
Trial: 6347108
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV methylprednisolone 15 mg every six hours for three days
Trial: 6347108
Drug: High- and
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High- and medium-dose groups combined
Trial: 28719155
Drug: Antipsychotic drug
RxNorm normalized name: antipsychotic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic drug treatment for 7 months
Trial: 25249568
Drug: Elagolix 150
RxNorm normalized name: elagolix 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elagolix 150 mg every day
Trial: 25249568
Drug: Elagolix 75
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix 75 mg twice a day
Trial: 25249568
Drug: Subcutaneous depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Trial: 15741771
Drug: Dose delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose delivered after inhalation of 20% of vital capacity (A)
Trial: 15741771
Drug: Dose delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose delivered after inhalation of 70% of vital capacity (B)
Trial: 1539845
Drug: Metoclopramide 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.25 mg/kg
Trial: 9679886
Drug: Irrigant volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigant volume increase (1,000 ml)
Trial: 8085380
Drug: Combined YF/ViPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined YF/ViPS vaccine (simultaneous administration)
Trial: 8085380
Drug: Combined YF/ViPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined YF/ViPS vaccine (combined administration)
Trial: 8085380
Drug: Single administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single administration of ViPS vaccine
Trial: 8085380
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of ViPS vaccine
Trial: 8085380
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of ViPS vaccine
Trial: 8085380
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (simultaneous or combined)
Trial: 2680356
Drug: Timentin (3.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timentin (3.1 g intravenously)
Trial: 2680356
Drug: Mezlocillin (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin (2.0 g intravenously)
Trial: 29955820
Drug: Caregiver-administered ORS
RxNorm normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver-administered ORS fluid monitoring charts
Trial: 23274782
Drug: Goal-directed haemodynamic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed haemodynamic treatment (GDHT) using fluids and dobutamine to attain oxygen delivery index >600 ml min(‐1) m(‐2)
Trial: 23274782
Drug: Routine fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine fluid treatment (RFT)
Trial: 19952844
Drug: EGCG (135-mg)
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG (135-mg)
Trial: 18729681
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management (CM) treatments
Trial: 16901645
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl (TDF: 12.5 microg/h)
Trial: 16901645
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl (TDF: 25 microg/h)
Trial: 16901645
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine (TDB: 35 microg/h)
Trial: 12112946
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of asymptomatic bacterial vaginosis
Trial: 12112946
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of Trichomonas vaginalis
Trial: 8148226
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of betamethasone 17-valerate (suspension in medical grade pressure sensitive adhesive applied to a 100 cm2 area for 28 hours)
Trial: 8148226
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 0.6 mg betamethasone
Trial: 8148226
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of betamethasone 17-valerate
Trial: 8148226
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of betamethasone
Trial: 3300292
Drug: Betaxolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol (mean dose of 22 mg for 12 weeks)
Trial: 3300292
Drug: Nadolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (mean dose of 103 mg for 12 weeks)
Trial: 2337121
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (protamine containing)
Trial: 2337121
Drug: Lente insulin
RxNorm normalized name: lente insulin, pork
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lente insulin (protamine free)
Trial: 1105698
Drug: Reserpine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reserpine (5 mg i.m.)
Trial: 21293107
Drug: Daivobet®/Dovobet® gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daivobet®/Dovobet® gel
Trial: 21293107
Drug: Tacalcitol ointment
RxNorm normalized name: tacalcitol
DrugBank: Tacalcitol (DB13689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacalcitol ointment
Trial: 20413372
Drug: Gel vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel vehicle alone
Trial: 17269993
Drug: High-dose proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose proton pump inhibitor
Trial: 15238986
Drug: CPT‐11+gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11+gemcitabine (1000 mg m(‐2), days 1 and 8; CPT‐11 300 mg m(‐2), day 8)
Trial: 15238986
Drug: CPT‐11 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11 (300 mg m(‐2), day 1)
Trial: 9571222
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral dose of [14C]irbesartan
Trial: 9571222
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg nonradiolabeled doses of irbesartan
Trial: 2455701
Drug: CVP chemotherapy
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CVP chemotherapy (3 cycles) followed by regional radiotherapy (40 to 50 Gy)
Trial: 2455701
Drug: BACOP chemotherapy
RxNorm normalized name: BACOPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BACOP chemotherapy (3 cycles) followed by regional radiotherapy (40 to 50 Gy)
Trial: 28506118
Drug: Fresh coconut
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Fresh Coconut Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh coconut (100 g)
Trial: 28506118
Drug: Groundnuts and
RxNorm normalized name: Bambara groundnut extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groundnuts and groundnut oil combination
Trial: 16879326
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of melatonin and 50 mg of zinc acetate alone
Trial: 16879326
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of melatonin and 50 mg of zinc acetate in addition to metformin
Trial: 15531007
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/d
Trial: 8738538
Drug: Daily recycled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily recycled bicarbonate hemodialysis
Trial: 1452502
Drug: Cefepime 1000
RxNorm normalized name: cefepime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 1000 mg bd by constant infusion over 30 min
Trial: 6230176
Drug: Metaproterenol (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol (1.3 mg)
Trial: 31766216
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD: 250 mg) of Amarasate®
Trial: 31766216
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (LD: 100 mg) of Amarasate®
Trial: 26810338
Drug: 41 mg
RxNorm normalized name: xylitol 141 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 41 mg enoxaparin subcutaneously plus 81 mg aspirin daily pre‐conception
Trial: 20134098
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea catechins (high-dose group, 580 mg daily for 2 weeks)
Trial: 20134098
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea catechins (medium-dose group, 80 mg daily for 2 weeks)
Trial: 20134098
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea catechins (control group, 0 mg daily for 2 weeks)
Trial: 12699026
Drug: Cognitive-Behavioral Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Treatment with Contingency Management (CBT + CM)
Trial: 1971445
Drug: Immediate Release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release (IR) 200 mg BID
Trial: 1971445
Drug: Controlled Release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled Release (CR) 400 mg once daily
Trial: 433821
Drug: Two whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two whole fresh eggs daily for 3 months
Trial: 30717112
Drug: cyano‐B12 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyano‐B12 (2 × 0.76 µg)
Trial: 30717112
Drug: cow milk
RxNorm normalized name: cow milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cow milk (2 × 200 mL)
Trial: 30717112
Drug: buffalo milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buffalo milk (2 × 200 mL)
Trial: 28654131
Drug: Topical oxybutynin
RxNorm normalized name: oxybutynin Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oxybutynin 10% gel
Trial: 28654131
Drug: Placebo compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo compound
Trial: 26775474
Drug: Huikangling Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huikangling Tablet (HT), 0.4 g per tablet, 3 tablets each time, three times per day for 12 weeks
Trial: 26775474
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (TSH suppression therapy only)
Trial: 26814307
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil 1,200 mg
Trial: 26814307
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil 2,400 mg
Trial: 26814307
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil 3,600 mg
Trial: 18455052
Drug: Letter explaining
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letter explaining the importance of influenza vaccine for HCW